Yaldizli, ÖzgürÖzgürYaldizliBenkert, PascalPascalBenkertAchtnichts, LutzLutzAchtnichtsBar-Or, AmitAmitBar-OrBohner-Lang, VivianeVivianeBohner-LangBridel, ClaireClaireBridelComabella, ManuelManuelComabellaFindling, OliverOliverFindlingDisanto, GiulioGiulioDisantoFinkener, SebastianSebastianFinkenerGobbi, ClaudioClaudioGobbiGranziera, CristinaCristinaGranzieraHerwerth, MarinaMarinaHerwerthHoepner, RobertRobertHoepnerHorakova, DanaDanaHorakovaKamber, NicoleNicoleKamberKhalil, MichaelMichaelKhalilKunz, PhilippPhilippKunzLalive, PatricePatriceLaliveLinker, RalfRalfLinkerLorscheider, JohannesJohannesLorscheiderMüller, StefanieStefanieMüllerOechtering, JohannaJohannaOechteringPettypool, VictoriaVictoriaPettypoolPiehl, FredrikFredrikPiehlPot, CarolineCarolinePotRoth, PatrickPatrickRothThéaudin, MarieMarieThéaudinTintore, MarMarTintoreTur, CarmenCarmenTurUffer, DenisDenisUfferUginet, MarjolaineMarjolaineUginetVehoff, JochenJochenVehoffWiendl, HeinzHeinzWiendlZiemssen, TjalfTjalfZiemssenZecca, ChiaraChiaraZeccaSalmen, AnkeAnkeSalmenLeppert, DavidDavidLeppertDerfuss, TobiasTobiasDerfussKappos, LudwigLudwigKapposHemkens, Lars GLars GHemkensJaniaud, PerrinePerrineJaniaudKuhle, JensJensKuhle2025-06-182025-06-182025-07https://boris-portal.unibe.ch/handle/20.500.12422/210746Background Serum neurofilament light (sNfL) chain levels, a sensitive measure of disease activity in multiple sclerosis (MS), are increasingly considered for individual therapy optimization yet without consensus on their use for clinical application. Objective We here propose treatment decision algorithms incorporating sNfL levels to adapt disease-modifying therapies (DMTs).Methods We conducted a modified Delphi study to reach consensus on algorithms using sNfL within typical clinical scenarios. sNfL levels were defined as "high" (>90th percentile) vs "normal" (<80th percentile), based on normative values of control persons. In three rounds, 10 international and 18 Swiss MS experts, and 3 patient consultants rated their agreement on treatment algorithms. Consensus thresholds were defined as moderate (50%-79%), broad (80%-94%), strong (≥95%), and full (100%). Results The Delphi provided 9 escalation algorithms (e.g. initiating treatment based on high sNfL), 11 horizontal switch (e.g. switching natalizumab to another high-efficacy DMT based on high sNfL), and 3 de-escalation (e.g. stopping DMT or extending intervals in B-cell depleting therapies). Conclusion The consensus reached on typical clinical scenarios provides the basis for using sNfL to inform treatment decisions in a randomized pragmatic trial, an important step to gather robust evidence for using sNfL to inform personalized treatment decisions in clinical practice.enDelphi studyde-escalationescalationpersonalized treatment strategiesserum neurofilament light chain600 - Technology::610 - Medicine & healtharticle10.48620/885794029636310.1177/13524585251335466